T Cell Cytokine Secretion Analysis Service
Overview
CD BioGlyco provides a specialized T cell cytokine secretion analysis service, categorized under our mRNA bioanalysis service within the broader mRNA-based vaccine development. T cells play a pivotal role in the immune response to mRNA-encoded antigens, and their ability to secrete specific cytokines, such as interferon-gamma (IFN-γ), interleukin-2 (IL-2), and tumor necrosis factor-alpha (TNF-α), is a primary indicator of vaccine potency and therapeutic efficacy. By measuring the concentration, frequency, and polyfunctionality of cytokine-secreting cells, we help researchers decipher the complex interactions between mRNA delivery systems and the host immune system. Whether you are optimizing a lipid nanoparticle (LNP) formulation or validating a new neoantigen candidate, our bioanalytical expertise ensures your project moves forward with confidence.
Key Technologies
- Enzyme-Linked Immunospot (ELISpot) and FluoroSpot
These assays allow for the detection of cytokine secretion at the single-cell level with unparalleled sensitivity. While ELISpot is the gold standard for quantifying the frequency of cytokine-producing cells, FluoroSpot enables the simultaneous detection of multiple cytokines from a single cell, providing a direct measure of polyfunctionality.
- Intracellular Cytokine Staining (ICS)
ICS is essential for identifying the specific cellular source of cytokines. By utilizing fluorochrome-conjugated antibodies and protein transport inhibitors, we simultaneously assess surface markers (e.g., CD3, CD4, CD8) and intracellular cytokines, offering a multidimensional view of the T cell response.
- Multiplex Bead-Based Immunoassays
Technologies such as electrochemiluminescence (ECL) allow for the high-throughput quantification of dozens of soluble cytokines in cell culture supernatants or serum. This provides a comprehensive "cytokine storm" or "inflammatory profile" from a single, small-volume sample.
Precision Immunomonitoring for Next-Gen mRNA Therapeutics
As part of our mRNA bioanalysis service, we offer a comprehensive suite of analysis methods tailored to the unique requirements of mRNA-based products. Our scope covers the characterization of various "sub-substances" and functional profiles:
- Th1/Th2/Th17 Polarization Analysis
We quantify the balance of T-helper (Th) cell responses. mRNA vaccines often aim for a Th1-biased response to ensure safety and avoid vaccine-associated enhanced respiratory disease (VAERD).
- Polyfunctional T Cell Indexing
We measure the ability of individual T cells to produce multiple cytokines simultaneously (e.g., IFN-γ, TNF-α). High polyfunctionality is frequently correlated with superior protective immunity.
- Kinetics of Cytokine Release
Our team performs longitudinal studies to track how cytokine levels evolve post-vaccination or post-treatment, providing critical data for dosage and scheduling optimization.
- Cross-Reactive T Cell Assessment
We evaluate the ability of mRNA-induced T cells to recognize and respond to variant antigens or related pathogen strains.
Workflow
Sample Preparation
We accept various sample types, including fresh whole blood or cryopreserved peripheral blood mononuclear cells (PBMCs). Our specialized protocols ensure maximum cell viability and recovery, which is critical for functional assays.
Antigenic Stimulation
Cells are stimulated with specific mRNA-encoded proteins, overlapping peptide pools, or even through direct transfection of the mRNA of interest. We include positive controls and negative controls to validate assay performance.
Incubation and Secretion Capture
For FluoroSpot, cells are incubated on membranes pre-coated with capture antibodies. For ICS, protein transport inhibitors are added to trap cytokines within the endoplasmic reticulum.
Immunoassay Labeling
Samples undergo multi-step staining. This includes surface marker labeling, cell fixation/permeabilization, and the addition of biotinylated or fluorescently labeled detection antibodies.
High-Parametric Data Acquisition
Using advanced flow cytometers or high-resolution plate readers, we capture raw signal data. Our equipment is calibrated daily to ensure sensitivity and minimize batch-to-batch variation.
Bioinformatic Analysis and Reporting
Raw data is processed using specialized software. We provide detailed reports including spot-forming unit (SFU) counts, gating strategies, population percentages, and statistical comparisons across experimental groups.
Publication Data
DoI: 10.1038/s41467-020-15543-y
Journal: Nature Communications
IF: 15.7
Published: 2020
Results: This study employs multi-omics (bulk RNA-seq and proteomics of over 40,000 cells) to investigate cytokine responses in human naïve (Tn) and memory (Tm) CD4+ T cells. Key findings reveal Tm cannot differentiate into Th2 and acquire a Th17-like phenotype under iTreg polarization, unlike Tn which respond to all tested cytokine conditions. Analyses identify a transcriptional continuum from Tn to central/effector memory T cells, forming an "effectorness gradient" with increased chemokine/cytokine expression. This gradient, linked to T cell activation history and clonal expansion, shapes responses to activation and cytokines, e.g., IFNγ secretion correlates with effectorness. The study highlights T cell heterogeneity, showing effectorness and cytokine stimulation jointly modulate transcriptomes, advancing understanding of inflammation and immune cell plasticity.
Fig.1 The experimental design of RNA-seq analysis. (Cano-Gamez, et al., 2020)
Applications
mRNA Vaccine Development
Quantitative assessment of T cell immunogenicity for infectious disease vaccines. Our data support "Go/No-Go" decisions during preclinical research.
Cancer Immunotherapy
Monitoring the activation and cytokine profiles of T cells targeting tumor-associated antigens (TAAs) or neoantigens delivered via mRNA platforms.
Adoptive Cell Therapy (ACT)
Evaluation of CAR-T or TCR-T cell functional potency. We measure cytokine secretion as a correlate of the cells' cytotoxic potential and persistence.
Autoimmune Disease Research
Investigating the modulation of regulatory T cell (Treg) cytokine profiles (e.g., IL-10, TGF-β) in response to tolerogenic mRNA therapies.
Advantages
High Sensitivity and Low Detection Limits
Our optimized ICS protocols detect rare antigen-specific T cell populations, with a limit of detection (LOD) as low as 1 in 100,000 cells.
Customizable Multiplex Panels
CD BioGlyco offers flexible panel designs, allowing you to choose from over 50 different human, mouse, or non-human primate (NHP) cytokines to fit your specific research goals.
Expert PhD-Level Consultation
Every project is overseen by experienced immunologists who assist in experimental design, antigen selection, and complex data interpretation, ensuring scientific rigor.
End-to-End mRNA Bioanalysis Integration
As a leader in the field, we seamlessly link cytokine analysis with other mRNA services, such as LNP characterization and mRNA integrity testing.
Frequently Asked Questions
Customer Review
Their T cell cytokine profiling was instrumental in demonstrating the Th1-bias of our candidate. The data was delivered ahead of schedule and met all our requirements.
— C.Y., Biopharma Corporation
The depth of information provided by their polyfunctional T cell indexing service allowed us to differentiate between three lead LNP formulations that appeared identical in initial screens.
— C.R., Biotech Research Institute
Reliable, professional, and scientifically rigorous. Their team's expertise in handling samples for our preclinical mRNA program was impressive. Highly recommended.
— B.W., Medical Center
Associated Services
At CD BioGlyco, we understand that the success of your mRNA-based therapy hinges on a deep understanding of the cellular immune response. Our T cell cytokine secretion analysis service combines cutting-edge technology with scientific expertise to provide the insights you need to advance your pipeline. Please feel free to contact us for detailed information on our services or to request a formal quotation.
Reference
- Cano-Gamez, E.; et al. Single-cell transcriptomics identifies an effectorness gradient shaping the response of CD4+ T cells to cytokines. Nature Communications. 2020, 11: 1801. (Open Access)
- Glyco™ Synthesis Platform
- Custom Glycoprotein Synthesis
- Custom Glycoside Synthesis
- Custom Glycosyl Donor Synthesis
- Custom Thioglycoside Synthesis
- Custom Phosphatidylinositol Synthesis
- Custom Cyclodextrin Synthesis
- Custom Rhamnolipid Synthesis
- Custom Sphingolipid Synthesis
- Custom Building Block Synthesis
- Carbohydrate Manufacturing
- Synthesis Process Development and Optimization
- Custom Carbohydrate Synthesis
- Custom Glycolipid Synthesis
- Custom Glycopeptide Synthesis
- Custom Glycoconjugate Synthesis
- Custom Sugar-Nucleotide Synthesis
- Nucleoside & Nucleotide Synthesis Service
- Custom Oligonucleotide Synthesis Service
- Polynucleotide Synthesis Service
- Nucleoside & Nucleotide Modification Service
- Oligonucleotide Modification Service
- Nucleoside-based Production Service
- Nucleotide-based Production Service
- OPME-based NDP-sugar Synthesis Service
- OPME-based NMP-sugar Synthesis Service
- Glycomics Platform
- Glycoproteomics Platform
- N-Glycoproteomics of PDX Models
- Nanotechnologies for the Detection of Glycopeptides
- Glycoprotein Enrichment
- Glycoprotein Quantification
- Glyco-biomarker Detection Service
- Glyco-biomarker AFP Detection Service
- Glyco-biomarker CA19-9 Detection Service
- Glyco-biomarker CA125 Detection Service
- Glyco-biomarker CA15–3 Detection Service
- Glyco-biomarker CEA Detection Service
- Glyco-biomarker PSA Detection Service
- Glyco-biomarker Immunoglobulin G (IgG) Detection Service
- Glyco-biomarker Haptoglobin (Hp) Detection Service
- Glyco-biomarker α1-Antitrypsin (A1AT) Detection Service
- Glyco-biomarker α1-Acid Glycoprotein (AGP) Detection Service
- Glyco-biomarker Ceruloplasmin (CP) Detection Service
- Glyco-biomarker Fetuin A Detection Service
- Site Occupation
- Glycoprotein Structure Analysis
- Glycosylation Site-specific Antibody-Drug Conjugate (ADC) Development Platform
- Carbohydrate-based Glycomedicine Development Platform
- By Sources of Carbohydrate
- By Types of Carbohydrate
- Monosaccharides-based Glycomedicine Development
- Disaccharides-based Glycomedicine Development
- Trisaccharides-based Glycomedicine Development
- Oligosaccharides-based Glycomedicine Development
- Polysaccharides-based Glycomedicine Development
- Glycosides-based Glycomedicine Development
- Glycopeptide-based Glycomedicine Development
- Glycomimetic-based Glycomedicine Development
- By Applications of-based Glycomedicines
- Carbohydrate-based Anticoagulant Glycomedicine Development
- Carbohydrate-based Cardiovascular Glycomedicine Development
- Carbohydrate-based Antitumor Glycomedicine Development
- Carbohydrate-based Antidiabetic Glycomedicine Development
- Carbohydrate-based Antibacterial Glycomedicine Development
- Carbohydrate-based Antiviral Glycomedicines Development
- Carbohydrate-based Antiparasiti Glycomedicine Development
- By Discovery Strategies
- Glycoengineering-based Glycomedicine Development
- Production of Food Ingredients
- Multi-omics Platform for Cancer Glucose Metabolism (MOPCGM)
- Cancer Cell Glycolytic Analysis
- Cancer Cell TCA Cycle Analysis
- Cancer Cell PPP Analysis
- Gene-level Regulation Analysis of Cancer Glucose Metabolism
- Interplay Between Glucose Metabolism Reprogramming and Tumorigenesis & Progression
- Interplay Between Glucose Metabolism Reprogramming and Proliferative Signaling
- Interplay Between Glucose Metabolism Reprogramming and Growth Suppressor
- Interplay Between Glucose Metabolism Reprogramming and Cancer Cell Death
- Interplay Between Glucose Metabolism Reprogramming and Replicative Immortality
- Interplay Between Glucose Metabolism Reprogramming and Angiogenesis
- Interplay Between Glucose Metabolism Reprogramming and Invasion & Metastasis
- Interplay Between Glucose Metabolism Reprogramming and Immune Escape
- Interplay Between Glucose Metabolism Reprogramming and Genomic Instability
- Interplay Between Glucose Metabolism Reprogramming and Tumor-associated Inflammation
- Glucose Metabolism-Microenvironment Crosstalk Analysis in Cancer
- Cancer Glucose Metabolism In Vivo Analysis
- Applications of Studing Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism Small Molecule Inhibitor
- Discovery of Cancer Glucose Metabolism Therapeutic Monoclonal Antibodies
- Development of Gene Therapy Targeting Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism CAR-T Therapy Targeting
- Discovery of Cancer Glucose Metabolism Combination Therapy Strategy
- Discovery of Cancer Glucose Metabolism Precision Therapeutic Strategies
- Glycoengineering Platform
- Therapeutic Nucleic Acid Development Platform
- Therapeutic Oligonucleotide Synthesis Service
- siRNA Synthesis
- miRNA Synthesis
- ASO Synthesis
- Aptamer Synthesis
- PMO Synthesis
- sgRNA Synthesis
- Circular RNA Synthesis
- PNA Synthesis
- Lipid-based GalNac-RNA Delivery Service
- CpG Oligonucleotide Synthesis
- Click-based GalNac-RNA Delivery Service
- AntimiR Synthesis
- GalNAc-siRNA Delivery Service
- tRNA Synthesis
- GalNAc-ASO Delivery Service
- saRNA Synthesis
- Reporter Gene mRNA Synthesis
- Gene Editing mRNA Synthesis
- Gene Replacement mRNA Synthesis
- Cre Recombinase mRNA Synthesis
- hEPO mRNA Synthesis
- OVA mRNA Synthesis
- Therapeutic Oligonucleotide Modification Service
- Therapeutic Oligonucleotide Delivery Development Service
- Targeted Ligand and Linker Synthesis
- Monoantennary GalNac-RNA Delivery
- Biantennary GalNac-RNA Delivery
- Triantennary GalNac-RNA Delivery
- Tetra-antennary GalNac-RNA Delivery
- Solution Phase-based GalNac-RNA Delivery
- Solid Phase-based GalNac-RNA Delivery
- mRNA Poly(A) Tail Length Analysis
- GalNAc-siRNA Delivery
- GalNAc-ASO Delivery
- GalNAc-miRNA Delivery
- GalNAc-Aptamer Delivery
- GalNAc-AntimiR Delivery
- GalNAc-mRNA Delivery
- GalNAc-PNA Delivery
- Peptide-Therapeutic Oligonucleotide Delivery
- LNP-Therapeutic Oligonucleotide Delivery
- PEG-Therapeutic Oligonucleotide Delivery
- Biological Evaluation Service for Therapeutic Oligonucleotide
- mRNA-based Vaccine Development Service
- mRNA Sequence Design&Optimization Service
- mRNA Integrity Analysis ServicemRNA Integrity Analysis Service
- mRNA Biodistribution Analysis Service
- DNA Template Preparation Service
- mRNA Purity Analysis Service
- T Cell Cytokine Secretion Analysis Service
- mRNA Modification Service
- mRNA Length Analysis Service
- mRNA Purification Service
- Neutralizing Antibody Assay Service
- mRNA-LNP Formulation and Encapsulation Service
- mRNA Structural Characterization
- mRNA Structural Characterization Service
- mRNA Bioanalysis Service
- mRNA Residual DNA Template Analysis Service
- mRNA Residual Double-Stranded RNA (dsRNA) Analysis Service
- mRNA Size Analysis Service
- mRNA Polydispersity Analysis Service
- mRNA Zeta Potential Analysis Service
- mRNA Lipid Composition Analysis Service
- Oligonucleotide Drug Process and Formulation Development Service
- RNA Drug Process and Formulation Development
- Therapeutic Oligonucleotide Synthesis Service
- Glycobiology Microarray Platform
- Glyco™ Vaccine Development Platform
- Carbohydrate-based Vaccine Development
- Polysaccharide Vaccine Development
- Tumor-Associated Carbohydrate Vaccine Development
- Glycoconjugate Vaccine Development
- Natural Carbohydrate-based Vaccine Development
- Semi-synthetic Carbohydrate-based Vaccine Development
- Fully Synthetic Carbohydrate-based Vaccine Development
- Carbohydrate-based Antibacterial Vaccine Development
- Carbohydrate-based Antifungal Vaccine Development
- Carbohydrate-based Antiparasitic Vaccine Development
- Carbohydrate-based Antiviral Vaccine Development
- Carbohydrate-based Anticancer Vaccine Development
- Carbohydrate-based Antihelmintic Vaccine Development
- Monovalent Carbohydrate-based Vaccine Development
- Polyvalent Carbohydrate-based Vaccine Development
- Carrier Protein Design Service
- Carbohydrate Conjugation Service for Vaccine Development
- Carbohydrate-based Adjuvant Development
- Lipopolysaccharide-based Adjuvant Development
- Bacterial Outer Membrane Vesicles (OMVs)-based Adjuvant Development
- Trehalose Glycolipid-based Adjuvant Development
- Galactosylceramide-based Adjuvant Development
- Peptidoglycan-based Adjuvant Development
- Chitin/Chitosan-based Adjuvant Development
- Inulin-based Adjuvant Development
- Mannans-based Adjuvant Development
- Alginate-based Adjuvant Development
- Saponin-based Adjuvant Development
- α-Glucan-based Adjuvant Development
- Lentinan-based Adjuvant Development
- β-Glucans-based Adjuvant Development
- Deltin-based Adjuvant Development
- Muramyldipeptide-based Adjuvant Development
- Cord Factor-based Adjuvant Development
- Zwitterionic Polysaccharide-based Adjuvant Development
- Novel Plant Polysaccharides-based Adjuvant Development
- Glycoprotein-based Vaccine Development
- Glycopeptide-based Vaccine Development
- Carbohydrate-based Vaccine Development
- Glycogenomics Platform
- Glycogene Editing Service
- Glycogene Delivery Service
- Glycogene Expression Profiling
- Cancer Glycogene Discovery Service
- Glycogene Discovery Service in Cervical Cancer
- Glycogene Discovery Service in Leukemia
- Glycogene Discovery Service in Bladder Cancer
- Glycogene Discovery Service in Colorectal Adenocarcinoma
- Glycogene Discovery Service in Liver Cancer
- Glycogene Discovery Service in Lymphoma
- Glycogene Discovery Service in Breast Cancer
- Glycogene Discovery Service in Prostate Cancer
- Glycogene Discovery Service in Pancreatic Cancer
- Glycogene Discovery Service in Lung Cancer
- Glycogene Discovery Service in Thyroid Cancer
- Glycogene Discovery Service in Ovarian Cancer
- Glycan Display Platform
- Traditional Glycan Display Array
- Natural Oligosaccharide Library Construction Service
- Chemical Synthesis-based Oligosaccharide Library Construction Service
- Enzymatic Synthesis-based Oligosaccharide Library Construction Service
- Modular Synthesis-based Oligosaccharide Library Construction Service
- Oligosaccharide Library Immobilization Service
- Cell-based Glycan Display Array
- Neoglycolipid (NGL) Display Array
- Liquid Glycan Display Array (LiGA)
- Glycophage Display
- N-linked Glycoprotein-based Glycophage Display System Construction Service
- O-linked Glycoprotein-based Glycophage Display System Construction Service
- Glycophage Display-based Glycosylase Genetic Analysis Service
- Glycophag Display-based Glycoarray Service
- Glycophage Display-based Antibody Development Service
- Glycophage Display-based Epitope Mapping Service
- Glycophage Display-based Biomarker Development Service
- De Novo Glycan Display
- Cell-Surface Glycan Editing
- Examining the Effects of Altering Blood Group Antigens on Erythrocyte Cell Surfaces
- Preventing Cellular Rejection During Transplantation
- Modulating Chemical Composition and Physical Parameters of Glycocalyx
- Tailoring Cell Membranes with Biologically Active Glycans
- Targeting Glycosaminoglycan-mediated Growth Factor Signaling to Influence Stem Cell Specification
- Long-term De Novo Glycan Display for Directing Stem Cell Fate
- Traditional Glycan Display Array
- GlycoNano™ Platform
- Glyconanoparticle Development Service
- Techniques for Glyconanoparticle Development
- Carbohydrate-based Nanoparticle Production
- Gold Glyconanoparticle Production
- Silver Glyconanoparticle
- Magnetic Glyconanoparticle
- Quantum Dot (QD) Glyconanoparticle
- Glyconanoparticle Characterization
- PEG Glyconanoparticle
- Carbon-based Glyconanoparticle
- Fluorescent Glyconanoparticle
- Silica Glyconanoparticle
- Liposome Glyconanoparticle
- Glycol Nanohydrogel Development
- Glycol Nanorod
- Glycol Nanotube
- Glycol Nanocrystal/Nanosheet/Nanosphere/Nanofiber
- Glyconanoparticle Preclinical Study
- Glyconanoparticle Formulation
- Glyconanotechnology-based Biosensor Development
- GlycoNano™ Bioink Production for 3D Printing
- Glyconanoparticle Development Service
- Glyco™ Synthesis Platform